Clinical Research of How Gegen Tongmaiyin Downregulating Plasma NF-B to Prevent Atherosclerosis

HU Hai-tao; ZHANG Yan; SHEN Xiao-jun; SUN Jie; WANG Tan

doi:10.11653/syfj2014040179

您当前的位置：

首页 >

文章列表页 >

Clinical Research of How Gegen Tongmaiyin Downregulating Plasma NF-B to Prevent Atherosclerosis

更新时间：2024-01-04

- Clinical Research of How Gegen Tongmaiyin Downregulating Plasma NF-B to Prevent Atherosclerosis
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 20, Issue 4, Pages: 179-182(2014)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.11653/syfj2014040179
  CLC：
- Published：2014
- 稿件说明：
移动端阅览
HU Hai-tao, ZHANG Yan, SHEN Xiao-jun, et al. Clinical Research of How Gegen Tongmaiyin Downregulating Plasma NF-B to Prevent Atherosclerosis[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(4): 179-182.
DOI：

HU Hai-tao, ZHANG Yan, SHEN Xiao-jun, et al. Clinical Research of How Gegen Tongmaiyin Downregulating Plasma NF-B to Prevent Atherosclerosis[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(4): 179-182. DOI： 10.11653/syfj2014040179.

摘要

目的：观察葛根通脉饮对动脉粥样硬化（AS）患者血清核转录因子（NF-κB）水平的影响，探讨其对AS的防治作用及相关机制。方法：符合入选标准的97例患者随机分为对照组和葛根通脉饮组（治疗组），对照组给予瑞舒伐他汀常规治疗，治疗组在常规治疗的基础上加用葛根通脉饮每日1剂，水煎服。8周后全自动生化仪检测血浆总胆固醇（TC），甘油三酯（TG），高密度脂蛋白（HDL），低密度脂蛋白（LDL），载脂蛋白A（ApoA），ApoB，脂蛋白a（Lpa）；酶联免疫吸附测定（ELISA法检测外周血NF-κB水平；飞利浦ie33超声机检测颈动脉内膜中膜厚度（IMT）、颈动脉AS斑块积分。结果：葛根通脉饮治疗后，血清TC，TG，LDL-C，ApoB，LPa 水平降低，血清HDL水平升高，与治疗前比较，差异显著（P<0.05，P<0.01）；治疗组治疗后血清TC，LDL-C，ApoB显著降低，与对照组比较差异显著（P<0.05），提示联合使用葛根通脉饮改善血脂的疗效优于常规治疗。颈动脉内膜中膜厚度检测及斑块积分情况显示，治疗组治疗后AS斑块明显消退，与治疗前及对照组治疗后比较，差异均有统计学意义（P<0.05）。治疗组NF-κB表达明显减少，与对照组相比差异显著（P<0.01）。结论：葛根通脉饮能有效的调节血脂水平，干预颈动脉AS斑块的发生发展，下调NF-κB水平是其抗AS作用机制之一。

Abstract

Objective: To study the influence of Gegen Tongmaiyin to plasma nuclear factor-kappaB(NF-κB) in patients with atherosclerosis

and explore its curative effect and mechanism. Method: Ninty-seven patients were randomly divided into control group and Gegen Tongmaiyin group(treatment group).Rosuvastatin was used to cure patients of control group.On the basis of this conventional treatment

Gegen Tongmaiyin was added to cure patients of treatment group

water decoction

one dose a day.After 8 weeks

plasma total cholesterol(TC)

triglycerides(TG)

high density lipoprotein(HDL)

low density lipoprotein(LDL)

apolipoprotein A(ApoA)

ApoB

lipoprotein(a)(Lpa) were detected by automatic biochemical analyzer. Plasma NF-κB was measured by ELISA. Philips ie33 ultrasound machine was used to measure carotid intima-media thickness (IMT) and Carotid atherosclerosis plaque integral. Result: Compared with before treatment

plasma TC

LDL-C

ApoB

Lpa strikingly decreased

and HDL strikingly increased(P<0.05

P<0.01).Compared with the control group

plasma TC

LDL-C

ApoB of treatment group significantly decreased after combination treatment with rosuvastatin and gegentongmaiyin (P<0.05).Which indicated curative effect of the combination of rosuvastatin and Gegen Tongmaiyin was superior to conventional treatment in curing atherosclerosis. Carotid intima-media thickness (IMT) and carotid atherosclerosis plaque integral showed atherosclerotic plaque of treatment group significantly diminished compared with before treatment and control group (P<0.05). Plasma NF-κB of treatment group significantly reduced in contrast to control group(P<0.01). Conclusion: Gegen Tongmaiyin can effectively adjust blood lipid levels

and then intervene the occurrence and development of Atherosclerotic plaque.Downregulating plasma NF-κB may be its mechanism of how to preventing atherosclerosis.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Gegen Tongmaiyin on Preventing Atherosclerosis by Down-regulating BIP Protein Expression

Exploration of Zhuyuwan in Treatment of Atherosclerosis from Perspective of Lipid Transport Disorder

Mechanism of Huangqi Chifengtang in Treating Atherosclerosis Based on 16S rRNA Sequencing and Metabolomics

Effect of Co-treatment Method of Stagnation of Phlegm and Blood Stasis （Danlou Tablet） on Vascular Endothelial Function in Patients with Atherosclerosis

Molecular Mechanism of Treating Different Diseases with Same Treatment of Gypenoside L Affecting Oxidative Damage HUVEC and OVCAR-3 Through EGFR/STAT3/Glycolytic Pathway

Related Author

XU Xue-qin

SONG Wei

ZHANG Zhongyi

QIU Hairong

ZHAO Mei

ZHOU Zubing

SHEN Tao

ZHANG Yong

Related Institution

Chengdu University of Traditional Chinese Medicine（TCM）

Hospital of Chengdu University of TCM

Hubei Minzu University

Institute of TCM， Sichuan Academy of Chinese Medicine Sciences

Institute of Traditional Chinese Medicine， Heilongjiang University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰